{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:33:31Z","timestamp":1770982411831,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Severance Regional Pharmacovigilance Center (Seoul, Korea)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The use of monoclonal antibodies (mAbs) is increasing in various clinical fields. Although mAb safety must be demonstrated prior to approval, targeted pharmacovigilance is essential for the recognition and assessment of adverse reactions. The purpose of this study was to identify the major clinical features of adverse reactions to mAbs in Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Spontaneous reports of adverse reactions attributed to 18 mAbs from January 2005 to December 2014 were extracted from the Korea Adverse Event Reporting System. We analyzed these reports for information relating to patient characteristics and the types of adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 11\u2009492 adverse reactions were reported in 7569 patients. Almost 19% of total study population showed suspected hypersensitivity reactions. Leukocyte abnormalities were reported frequently (10.0%), as well as infections (9.5%), drug eruptions (7.5%), and pruritus (5.0%). Furthermore, 3716 of the adverse reactions in 2538 patients were classified as serious; these included severe infections (18.2%), neutropenia (12.1%), visual dysfunctions (6.6%), and anaphylaxis (4.8%). The mAbs with the highest number of adverse reaction reports were rituximab (27.6%), adalimumab (17.5%), cetuximab (11.9%), and infliximab (10.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hypersensitivity reactions were observed more frequently than expected, although no previously unrecognized reactions were observed. Adverse reactions occurred more frequently in children and in elderly patients. Close monitoring of adverse reactions to therapeutic mAbs is therefore warranted because these can potentially cause serious medical conditions or death. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4049","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T06:26:13Z","timestamp":1467354373000},"page":"1279-1286","source":"Crossref","is-referenced-by-count":11,"title":["Clinical characteristics of adverse events associated with therapeutic monoclonal antibodies in Korea"],"prefix":"10.1002","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-0720","authenticated-orcid":false,"given":"Da Woon","family":"Sim","sequence":"first","affiliation":[{"name":"Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Severance Hospital Regional Pharmacovigilance Center Yonsei University College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Severance Hospital Regional Pharmacovigilance Center Yonsei University College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jung","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Severance Hospital Regional Pharmacovigilance Center Yonsei University College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Woong","family":"Son","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Severance Hospital Regional Pharmacovigilance Center Yonsei University College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Chul","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Severance Hospital Regional Pharmacovigilance Center Yonsei University College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung\u2010Won","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Severance Hospital Regional Pharmacovigilance Center Yonsei University College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae\u2010Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Severance Hospital Regional Pharmacovigilance Center Yonsei University College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"FDA Regulation of Follow\u2010on Biologics","author":"Johnson JA","year":"2009"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.2.15005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.02.014"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01058.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1085"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2006.04.001"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/428169"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000092358.51502.C0"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389201023378175"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2014.6.6.485"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2015.7.4.312"},{"issue":"4","key":"e_1_2_8_13_1","first-page":"212","article-title":"Hypersensitivity reactions to biological drugs","volume":"24","author":"Corominas M","year":"2014","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2014.6.2.156"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.16.1887"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"issue":"4","key":"e_1_2_8_17_1","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong SS","year":"2007","journal-title":"Journal of Rheumatology"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32835bf3f5"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.009"},{"issue":"2","key":"e_1_2_8_20_1","first-page":"89","article-title":"Pharmacovigilance system in general hospitals applied for the regional pharmacovigilance center in Korea","volume":"2","author":"Kim Y\u2010J","year":"2009","journal-title":"Journal of Pharmacoepidemiol Risk Management"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199819010-00001"},{"key":"e_1_2_8_22_1","volume-title":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD)","author":"Organization WH","year":"2006"},{"key":"e_1_2_8_23_1","unstructured":"Organization WH.Adverse reactions terminology (WHO\u2010ART).World Health Organization2005."},{"key":"e_1_2_8_24_1","volume-title":"The Use of the WHO\u2010UMC System for Standardized Case Causality Assessment","author":"Organization WH","year":"2005"},{"key":"e_1_2_8_25_1","volume-title":"Korean Standard Classification of Diseases","author":"Korea S","year":"2010"},{"issue":"10","key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","article-title":"Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting","volume":"140","author":"Nebeker JR","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e328355b7e4"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02799-9"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.4166\/kjg.2009.54.2.108"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081324"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357711"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2014.985547"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcs015"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029694"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.009"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130526"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120687"},{"issue":"6","key":"e_1_2_8_40_1","first-page":"292","article-title":"BIOBADASER: registro espa\u00f1ol de acontecimientos adversos de terapias biol\u00f3gicas en enfermedades reum\u00e1ticas","volume":"29","author":"Espa\u00f1ola CCBS","year":"2002","journal-title":"Revista Espa\u00f1ola de Reumatolog\u00eda"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464160-00004"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.all.0000136757.58818.10"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1543-5946(03)90004-3"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2429"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132916"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0494-6"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1196"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127009803801103"},{"issue":"1","key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.4103\/0976-500X.120942","article-title":"Pharmacovigilance in Italy: an overview","volume":"4","author":"Mazzitello C","year":"2013","journal-title":"Journal of Pharmacology and Pharmacotherapeutics"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200607-995OC"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21869"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27511"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4049","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T04:14:34Z","timestamp":1696392874000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/pds.4049"],"URL":"https:\/\/doi.org\/10.1002\/pds.4049","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}